Patents by Inventor William Mallet

William Mallet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF
    Publication number: 20240033370
    Abstract: The invention provides immunoconjugates of Formula I comprising an anti-PD-L1 antibody linked by conjugation to one or more 8-Cyc-2-aminobenzazepine derivatives. The invention also provides 8-Cyc-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 1, 2024
    Applicant: BOLT BIOTHERAPEUTICS, INC.
    Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, David DORNAN, Marcin KOWANETZ, Romas KUDIRKA, Arthur LEE, William MALLET, Brian SAFINA, Matthew ZHOU
  • CKIT antibody drug conjugates
    Patent number: 11833215
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 5, 2023
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20230086603
    Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.
    Type: Application
    Filed: January 21, 2021
    Publication date: March 23, 2023
    Applicant: BOLT BIOTHERAPEUTICS, INC
    Inventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20230069055
    Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.
    Type: Application
    Filed: January 21, 2021
    Publication date: March 2, 2023
    Applicant: BOLT BIOTHERAPEUTICS, INC
    Inventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
  • ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF
    Publication number: 20220195066
    Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: BOLT BIOTHERAPEUTICS, INC.
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
  • Immunoconjugates Targeting CEA
    Publication number: 20220152215
    Abstract: The invention provides an immunoconjugate of formula (I) or (II) Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen (“CEA”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 19, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou, Edgar George Engleman
  • CKIT ANTIBODY DRUG CONJUGATES
    Publication number: 20200405875
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 31, 2020
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William Mallet, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • CKIT antibody drug conjugates
    Patent number: 10786578
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • Anti-PMEL17 antibodies and immunoconjugates
    Patent number: 10196454
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: February 5, 2019
    Assignee: Genentech, Inc.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20180344864
    Abstract: The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark DENNIS, William MALLET, Paul POLAKIS
  • CKIT ANTIBODY DRUG CONJUGATES
    Publication number: 20180193475
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: July 27, 2015
    Publication date: July 12, 2018
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William MALLET, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20170240645
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: February 6, 2017
    Publication date: August 24, 2017
    Applicant: GENENTECH, INC.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • Anti-PMEL17 antibodies and immunoconjugates
    Patent number: 9597411
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: March 21, 2017
    Assignee: Genentech, Inc.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20160296634
    Abstract: The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 19, 2015
    Publication date: October 13, 2016
    Applicant: GENENTECH, INC.
    Inventors: Mark DENNIS, William MALLET, Paul POLAKIS
  • ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20150374847
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: May 6, 2015
    Publication date: December 31, 2015
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • Anti-PMEL17 antibodies and immunoconjugates
    Patent number: 9056910
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: June 16, 2015
    Assignee: Genentech, Inc.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20140314794
    Abstract: The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: December 17, 2013
    Publication date: October 23, 2014
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, William Mallet, Paul Polakis
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20140205616
    Abstract: The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: December 17, 2013
    Publication date: July 24, 2014
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, William Mallet, Paul Polakis
  • Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
    Patent number: RE47194
    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p ??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: January 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Jagath R. Junutula, William Mallet
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: RE47223
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 5, 2019
    Assignee: GENENTECH, INC.
    Inventors: Mark S. Dennis, Paul Polakis, William Mallet